Cargando…

Role of sodium‐glucose transporters in glucose uptake of the intestine and kidney

Detalles Bibliográficos
Autores principales:	Harada, Norio, Inagaki, Nobuya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley-Blackwell 2012
Materias:	Commentaries
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4019254/ https://www.ncbi.nlm.nih.gov/pubmed/24843589 http://dx.doi.org/10.1111/j.2040-1124.2012.00227.x

Ejemplares similares

Regulation of food intake by intestinal hormones in brain
por: Harada, Norio, et al.
Publicado: (2021)

Role of clock genes in insulin secretion
por: Harada, Norio, et al.
Publicado: (2016)

Effects of metformin on blood glucose levels and bodyweight mediated through intestinal effects
por: Harada, Norio
Publicado: (2020)

Mechanisms of fat‐induced gastric inhibitory polypeptide/glucose‐dependent insulinotropic polypeptide secretion from K cells
por: Yamane, Shunsuke, et al.
Publicado: (2016)

Update on the efficacy and safety of sodium–glucose cotransporter 2 inhibitors in Asians and non‐Asians
por: Fujita, Yoshihito, et al.
Publicado: (2019)

Sodium-glucose cotransporter 2 (SGLT-2) inhibition and kidney protection: Does improvement in kidney hypoxia play a role?
por: Burnier, Michel
Publicado: (2021)

Putting Rac1 on the Path to Glucose Uptake
por: Rudich, Assaf, et al.
Publicado: (2013)

Sodium-dependent glucose transporter 1 and glucose transporter 2 mediate intestinal transport of quercetrin in Caco-2 cells
por: Li, Suyun, et al.
Publicado: (2020)

Control of intestinal stem cell fate: A novel approach to treating diabetes
por: Yamane, Shunsuke, et al.
Publicado: (2015)

Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes?
por: Yurista, Salva R., et al.
Publicado: (2020)

Effects of glucose and meal ingestion on incretin secretion in Japanese subjects with normal glucose tolerance
por: Yamane, Shunsuke, et al.
Publicado: (2011)

The Benefit of Sodium-Glucose Co-Transporter Inhibition in Heart Failure: The Role of the Kidney
por: Gronda, Edoardo, et al.
Publicado: (2022)

Sodium, Glucose and Dysregulated Glucagon Secretion: The Potential of Sodium Glucose Transporters
por: Armour, Sarah L., et al.
Publicado: (2022)

Combined effect of sodium–glucose cotransporter 2 and dipeptidyl peptidase‐4 inhibitors for diabetic kidney disease
por: Araki, Shin‐ichi
Publicado: (2019)

Exploration of the clinical benefits of sodium glucose co-transporter 2 inhibitors in diabetic patients with concomitant heart failure
por: Tanaka, Atsushi, et al.
Publicado: (2018)

Sodium-glucose co-transporter 2 inhibitors in COVID-19: meeting at the crossroads between heart, diabetes and infectious diseases
por: Koufakis, Theocharis, et al.
Publicado: (2021)

ContRac1ion-Mediated Glucose Uptake: A Central Role for Rac1
por: Lundell, Leonidas S., et al.
Publicado: (2013)

Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action
por: Fujita, Yoshihito, et al.
Publicado: (2014)

Sodium-Glucose Linked Transporter-2 Inhibitors in Chronic Kidney Disease
por: Zanoli, L., et al.
Publicado: (2015)

Editorial: Sodium Glucose Co-Transporter 2 Inhibitors and Kidney Function
por: Van Raalte, Daniel H., et al.
Publicado: (2022)

Intra‐ and inter‐subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co‐transporter 2 inhibitor canagliflozin
por: Polidori, David, et al.
Publicado: (2018)

Emerging Role of Sodium–Glucose Co-Transporter 2 Inhibitors for the Treatment of Chronic Kidney Disease
por: Isidto, Rey, et al.
Publicado: (2023)

Plasma gastric inhibitory polypeptide and glucagon‐like peptide‐1 levels after glucose loading are associated with different factors in Japanese subjects
por: Harada, Norio, et al.
Publicado: (2010)

Liver autophagy-induced valine and leucine in plasma reflect the metabolic effect of sodium glucose co-transporter 2 inhibitor dapagliflozin
por: Furuya, Futoshi, et al.
Publicado: (2022)

GLUT3 regulates alternative macrophage signaling through a glucose transport–independent role
por: Zhang, Peng, et al.
Publicado: (2023)

Role of Reactive Oxygen Species in Glucose Metabolism Disorder in Diabetic Pancreatic β-Cells
por: Mukai, Eri, et al.
Publicado: (2022)

Sodium–glucose cotransporter 2 inhibitors: A drug with antidiabetic and cardioprotective properties
por: Li, Hung‐Yuan
Publicado: (2020)

Attenuated secretion of glucose-dependent insulinotropic polypeptide (GIP) does not alleviate hyperphagic obesity and insulin resistance in ob/ob mice
por: Shimazu-Kuwahara, Satoko, et al.
Publicado: (2017)

The Effect of Potassium on the Intestinal Transport of Glucose
por: Csáky, T. Z., et al.
Publicado: (1966)

Glucose transport in the regulation of T-cell activation: the journey may be as important as the destination
por: Barger, Steven W.
Publicado: (2022)

How should we monitor the cardiovascular benefit of sodium–glucose cotransporter 2 inhibition?
por: Tanaka, Atsushi, et al.
Publicado: (2020)

“Greedy Organs Hypothesis” for sugar and salt in the pathophysiology of non-communicable diseases in relation to sodium-glucose co-transporters in the intestines and the kidney
por: Itoh, Hiroshi, et al.
Publicado: (2022)

In Vitro Effect of Fenugreek Extracts on Intestinal Sodium-dependent Glucose Uptake and Hepatic Glycogen Phosphorylase A
por: Al-Habori, M., et al.
Publicado: (2001)

Sodium glucose co-transporter 2 inhibition: a new avenue to protect the kidney
por: Heerspink, Hiddo J L
Publicado: (2019)

The Sympathetic Nervous System Regulates Sodium Glucose Co-Transporter 1 Expression in the Kidney
por: Matthews, Jennifer, et al.
Publicado: (2023)

Characterizing Adrenergic Regulation of Glucose Transporter 4-Mediated Glucose Uptake and Metabolism in the Heart
por: Jovanovic, Aleksandra, et al.
Publicado: (2023)

Reduction in the incidence of myocardial infarction with sodium–glucose linked cotransporter-2 inhibitors: evident and plausible
por: Gilbert, Richard E., et al.
Publicado: (2019)

Lowering the risk of gout: Another benefits from the use of sodium–glucose cotransporter 2 inhibitors
por: Sheu, Wayne H‐H
Publicado: (2020)

Incidence of severe urinary tract infections not increased by initiating sodium–glucose cotransporter 2 inhibitors
por: Yokoyama, Hiroki
Publicado: (2020)

Sodium‐glucose co‐transporter 2 inhibitor therapy: use in chronic kidney disease and adjunctive sodium restriction
por: Tiwary, Mansi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3q4246css3miu3t98e3gla09to